Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) European Union - English - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance

Tremelimumab AstraZeneca European Union - English - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - carcinoma, non-small-cell lung - antineoplastic agents - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Oxis 6 Turbohaler United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

oxis 6 turbohaler

astrazeneca uk ltd - formoterol fumarate dihydrate - inhalation powder - 6microgram/1dose

Oxis 12 Turbohaler United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

oxis 12 turbohaler

astrazeneca uk ltd - formoterol fumarate dihydrate - inhalation powder - 12microgram/1dose

VAXZEVRIA (previously COVID-19 Vaccine AstraZeneca) (ChAdOx1-S) solution for injection multidose vial Australia - English - Department of Health (Therapeutic Goods Administration)

vaxzevria (previously covid-19 vaccine astrazeneca) (chadox1-s) solution for injection multidose vial

astrazeneca pty ltd - chadox1-s, quantity: 100000000000 vp/ml - injection, solution - excipient ingredients: histidine; magnesium chloride hexahydrate; sucrose; disodium edetate; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate; ethanol absolute; water for injections - vaxzevria has provisional approval for the indication:,active immunisation of individuals greater than or equal to 18 years old for the prevention of coronavirus disease 2019 (covid-19) caused by sars-cov-2.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short term efficacy and safety data. continued approval is dependent upon the evidence of longer-term efficacy and safety from ongoing clinical trials and post-market assessment.